Abstract: A method, system, and non-transitory computer readable medium for predicting cell viability of a cell culture in a bioreactor during a biomolecule manufacturing process are disclosed. In various embodiments, at least three manufacturing process parameters related to the process for manufacturing molecules are input into a machine learning model that is trained to predict cell viabilities. The trained machine learning model may then analyze the at least three manufacturing process parameters to generate an indicator of cell viability of the cell culture.

Abstract: The present invention relates to the field of protein purification. In particular, the invention concerns methods for increasing the filtration capacity of virus filters, by combined use of endotoxin removal and cation-exchange media in the prefiltration process.

Abstract: The present disclosure relates to methods and compositions useful for measuring the transcytosis or recycling of a molecule. In particular, the present disclosure relates to in vitro receptor-dependent transcytosis or recycling assays for evaluating the clearance rates of therapeutic antibody molecules and Fc-fusion proteins in humans and animals.

Abstract: The invention provides anti-KLK7 antibodies, anti-KLK5 antibodies, anti-KLK5/KLK7 multispecific antibodies, and methods of using the same.

Abstract: The present disclosure relates to techniques for abstraction of unstructured clinical trial health data. Particularly, aspects are directed to obtaining, by a data transformation system, an unstructured document that includes various types of content for a given event. The data transformation system converts the unstructured document from an original format into a standardized format. The data transformation system processes the unstructured document in the standardized format to identify template-mapped content data and processes the template-mapped content data to identify high-interest content data. The data transformation system generates a dictionary data structure comprising key-value pairs for each of the template-mapped content data and the high-interest content data. The data transformation system generates a structured document based on the dictionary data structure for each of the template-mapped content data and the high-interest content data.

Abstract: The present disclosure relates to methods of administering Compound I for treating fibrotic disorders, inflammatory disorders or autoimmune disorders.

Abstract: The invention provides anti-Jagged2 antibodies and methods of using the same.

Abstract: Methods of treating Alzheimer's Disease (AD) in patients suffering from early AD, including amyloid positive patients, ApoE4 positive patients, and patients suffering from prodromal or mild AD are provided.

Abstract: The invention provides FGFR1 agonists, including agonistic anti-FGFR1 antibodies, and methods of using the same.

Abstract: Provided herein are combination therapies comprising GDC-9545 and a CDK4/6 inhibitor for treating locally advanced breast cancer or metastatic breast cancer.

Abstract: The invention provides isoform-selective anti-TGF? antibodies and methods of using the same. In particular, isoform-selective anti-TGF?2, anti-TGF?3, and anti-TGF?2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGF?-related disorders.

Abstract: The invention provides anti-Tau antibodies and methods of using the same.

Abstract: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.

Abstract: Described herein are Fc variants and methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins). Heteromultimeric proteins may be capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.

Abstract: Provided herein are methods of preparing a poloxamer for use in a cell culture medium. Also provided herein are cell culture media containing the poloxamer prepared by the methods herein, as well as methods of using the media for cell culturing and polypeptide production from cells.

Abstract: The present invention generally relates to nanolipoprotein particle conjugates comprising at least one polypeptide and nanolipoprotein particle conjugates comprising at least one short peptide between 20-60 amino acids in length. Also provided are related compositions and systems, and methods of preparing and using same. In particular, nanolipoprotein particle (NLP) conjugates with antigen-binding fragments (Fabs) are provided, where the NLP comprises a bilayer of membrane-forming lipids encircled by scaffold proteins, and the Fabs are conjugated to one or both bilayer surfaces. In some embodiments, the (NLP) conjugates further comprise a short peptide 20-60 amino acids in length.

Abstract: The present disclosure provides polysorbate 20 compositions with particular fatty acid ester concentrations. In some embodiments, they may be used in pharmaceutical formulations, for example, to improve stability.

Abstract: Cell culture media, such as chemically defined cell culture media, are provided, as are methods of using the media for cell growth (i.e., cell culture) and polypeptide (e.g., antibody) production. Compositions comprising polypeptides produced by the methods are also provided.

Abstract: Drug delivery systems and methods of use thereof for recording administration of a drug dose to a subject are provided. Aspects of the invention include a syringe stopper rod comprising a sensor component that is configured to detect a delivery signature, and to transmit a report comprising a drug dose completion signal to a data management component, e.g., a mobile computing device.

Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.